Abstract
We reviewed the reports of 784 consecutive patients admitted to our department for newly diagnosed acute myeloid leukemia (AML) over a 16-year period. Median, 5-year and 10-year overall survivals were 9.5 months, 17.3% and 11.7% respectively. Induction treatment (698 patients) resulted in 50% complete remissions (CR) (from 26.5% in secondary AML to 81.2% in patients <60 years with de novo AML). Period of diagnosis (1980–84/85–89/90–95) demonstrated a major significance for CR achievement and OS in multivariate analysis. In patients ⩾60 years (372), CR rate increased (25% to 36.8%, P = 0.03), and 5-year OS (3.7% to 10.6%, P = 0.022) improved, probably due to an increase in the proportion of patients administered conventional combined chemotherapy (54.5% to 83.8%, P < 0.0001). in younger patients cr rate continuously increased (61.5% to 74.8%, P = 0.028) with an associated improvement of 5-year OS (19.2% to 35.4%). No significant change in DFS and CR durations was observed. This large single center study on a large cohort of unselected AML patients reflects the improvement achieved in the management of AML patients, likely due to improvement of supportive care practices, administration of conventional induction to more elderly patients, and intensification of induction and post-remission treatments in patients <60 years.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Baudard, M., Beauchamp-Nicoud, A., Delmer, A. et al. Has the prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16-year period. Leukemia 13, 1481–1490 (1999). https://doi.org/10.1038/sj.leu.2401544
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401544
Keywords
This article is cited by
-
Post-Induction Treatment for Acute Myeloid Leukemia: Something Change?
Current Oncology Reports (2021)
-
New directions for emerging therapies in acute myeloid leukemia: the next chapter
Blood Cancer Journal (2020)
-
Leukemia targeting ligands isolated from phage display peptide libraries
Leukemia (2007)
-
Incidence and prognostic value of respiratory events in acute leukemia
Leukemia (2004)
-
WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies
Leukemia (2003)